<DOC>
	<DOC>NCT02946463</DOC>
	<brief_summary>The purpose of this study is to assess ALXN1210 compared to eculizumab in adult patients with PNH who have not previously used a complement inhibitor.</brief_summary>
	<brief_title>ALXN1210 Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<mesh_term>Complement System Proteins</mesh_term>
	<mesh_term>Complement Inactivating Agents</mesh_term>
	<criteria>1. Male or female ≥ 18 years of age. 2. PNH diagnosis confirmed by documented by highsensitivity flow cytometry. 3. Presence of 1 or more of the following PNHrelated signs or symptoms within 3 months of Screening: fatigue, hemoglobinuria, abdominal pain, shortness of breath (dyspnea), anemia (hemoglobin &lt;10 g/dL), history of a major adverse vascular event (including thrombosis), dysphagia, or erectile dysfunction; or history of pRBC transfusion due to PNH. 4. LDH level ≥ 1.5 × ULN at screening. 5. Documented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study treatment. 6. Female patients of childbearing potential must use highly effective contraception starting at screening and continuing until at least 8 months after the last dose of ALXN1210. 7. Willing and able to give written informed consent and comply with study visit schedule. 1. Treatment with a complement inhibitor at any time. 2. History of bone marrow transplantation. 3. Body weight &lt; 40 kilograms. 4. Females who are pregnant, breastfeeding or who have a positive pregnancy test at screening or Day 1. 5. Participation in another interventional clinical study or use of any experimental therapy within 30 days before initiation of study drug on Day 1 in this study or within 5 halflives of that investigational product, whichever is greater. 6. History of or ongoing major cardiac, pulmonary, renal, endocrine, or hepatic disease that, in the opinion of the investigator or sponsor, would preclude participation. 7. Unstable medical conditions (eg, myocardial ischemia, active gastrointestinal bleed, severe congestive heart failure, anticipated need for major surgery within 6 months of randomization, coexisting chronic anemia unrelated to PNH).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>